First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
Kim CG, Kim M, Hwang J, Kim ST, Jung M, Kim KH, Kim KH, Chang JS, Koom WS, Roh MR, Chung KY, Kim TM, Kim SK, Lee J, Shin SJ.
Kim CG, et al.
J Am Acad Dermatol. 2022 Nov;87(5):989-996. doi: 10.1016/j.jaad.2022.07.057. Epub 2022 Sep 6.
J Am Acad Dermatol. 2022.
PMID: 36068115